grant
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
Organization UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHLocation SALT LAKE CITY, UNITED STATESPosted 1 Sept 2024Deadline 31 May 2028
NIHUS FederalResearch GrantFY202521+ years oldAdenocarcinomaAdultAdult HumanAffectAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitionAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitionAngiogenic InhibitorsAngiostatic AgentsAnimalsAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAnti-VEGFAnti-VEGF Humanized Monoclonal AntibodyAnti-VEGF RhuMAbAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAntibodiesAttenuatedAtypical Glandular HyperplasiaAtypical adenomatous hyperplasiaAwarenessBindingBiologyBlood ClottingBlood Coagulation DisordersBlood VesselsBlood coagulationBody TissuesCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCO2Cancer GenesCancer ModelCancer PatientCancer TreatmentCancer-Promoting GeneCancerModelCancersCarbon DioxideCarbonic AnhydrideCategoriesCell BodyCell Communication and SignalingCell SignalingCellsCellular Immune FunctionCheckpoint inhibitorClinicClinical ResearchClinical StudyClinical Treatment MoabCoagulation DisorderCoagulopathyCollaborationsColon or RectumColorectalDataDeteriorationDevelopmentDiseaseDisorderDoseDrug KineticsDrug or chemical Tissue DistributionDrug usageDrugsEndothelial CellsEndothelial Growth Factors ReceptorEnsureFLK1Generalized GrowthGenesGeneticGrowthHealthHumanHypertensionHypothyroidismImmuneImmune checkpoint inhibitorImmune mediated therapyImmunesImmunityImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIntestinalIntestinesIntracellular Communication and SignalingKDR geneKO miceKidneyKidney Urinary SystemKnock-outKnock-out MiceKnockoutKnockout MiceLYT3LifeLungLung NeoplasmsLung Respiratory SystemLung TumorMalignantMalignant - descriptorMalignant AdenomaMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMoAb VEGFModelingModern ManMolecularMolecular InteractionMolecular TargetMolecular WeightMonoclonal AntibodiesMonoclonal Antibody Anti-VEGFMonoclonal Antibody TherapyMurineMusNSCLCNSCLC - Non-Small Cell Lung CancerNeoplasm MetastasisNeovascularization InhibitorsNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNormal TissueNormal tissue morphologyNull MouseNutrientO elementO2 elementOncogenesOrganism-Level ProcessOrganismal ProcessOxygenPTK InhibitorsPTK ReceptorsPathologicPathway interactionsPatientsPerforationPerfusionPharmaceutical PreparationsPharmacodynamicsPharmacokineticsPhenotypePhysiologicPhysiologic AngiogenesisPhysiologic NeovascularizationPhysiologic ProcessesPhysiologicalPhysiological AngiogenesisPhysiological NeovascularizationPhysiological ProcessesPlayProcessProtein Tyrosine Kinase InhibitorsProteinsProteinuriaPulmonary CancerPulmonary NeoplasmsPulmonary malignant NeoplasmReceptor ProteinReceptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase GeneRecombinant Humanized Anti-VEGF Monoclonal AntibodyRecombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth FactorRegulatory T-LymphocyteReportingResistanceRhuMAb VEGFRoleSafetySecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSignaling MoleculeSpeedStarvationT cell infiltrationT8 CellsT8 LymphocytesTK InhibitorsTesticlesTestingTestisTherapeuticTimeTissue DistributionTissue GrowthTissuesTransforming GenesTransmembrane Receptor Protein Tyrosine KinaseTreatment EfficacyTregTumor AngiogenesisTumor ImmunityTumor TissueTyrosine Kinase InhibitorTyrosine Kinase Linked ReceptorsTyrosine Kinase ReceptorsVEGFVEGF ReceptorsVEGFRVEGFR-2VEGFR2VEGFsVPF ReceptorVascular Endothelial Cell Growth Factor ReceptorVascular Endothelial Growth Factor Receptor 2Vascular Endothelial Growth FactorsVascular Hypertensive DiseaseVascular Hypertensive DisorderVascular Permeability Factor ReceptorVascular blood supplyVascularizationWound Repairadulthoodangiogenesisanti-cancer therapyanti-tumor immunityantiangiogenicantitumor immunityattenuateattenuatesbevacizumabbiological signal transductionbleeding disorderblood supplyblood vessel developmentblood vessel formationbowelcancer cellcancer immunitycancer metastasiscancer microenvironmentcancer progressioncancer therapycancer-directed therapychemotherapeutic agentchemotherapeutic compoundschemotherapeutic drugschemotherapeutic medicationschemotherapychip modelchip systemclotting disordercolorectumcytotoxicdensitydevelopmentaldrug usedrug/agentexperimentexperimental researchexperimental studyexperimentsgene functionhigh blood pressurehyperpiesiahyperpiesishypertensive diseasehypertensive disorderimmune check point inhibitorimmune functionimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimprovedintervention efficacylung cancermAB-based therapymAb therapymAb-based therapeuticsmAbsmale fertilitymalignancymonoclonal Absneoplasm progressionneoplasm/cancerneoplastic progressionneutralizing mAbneutralizing monoclonal antibodiesnovelon a chipon chipontogenypathwaypharmacodynamic biomarkerpharmacodynamic markerpre-clinical studypreclinical studyprion-likereceptorregulatory T-cellsrenalresistantresponserestraintrhuMabVEGFselective expressionselectively expressedside effectsocial roletherapeutic efficacytherapy efficacythrombotictumortumor cell metastasistumor growthtumor immune microenvironmenttumor microenvironmenttumor progressiontumor-immune system interactionstumorigenicvascularvascular bedvascular supplywastingwound healingwound recoverywound resolution
Description preview
Project summary
Tumors, just like normal tissues, require blood vessels to receive nutrients and oxygen and to eliminate wastes and
carbon dioxide. To ensure this blood supply, tumors create their own vascular beds from established blood vessels
by a process called angiogenesis. This process plays a major role in tumor growth, survival, and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click